Compuware zAdviser Delivers Actionable Analytic Insight to Continuously Improve Quality, Velocity and Efficiency on the Mainframe
Innovative Machine Learning Helps IT Leaders Pinpoint Opportunities to Boost DevOps Processes and Development Outcomes
- Enterprises dependent on mainframe applications must aggressively improve DevOps quality, velocity and efficiency-even as responsibilities shift to less experienced internal teams and/or outsourcing partners.
- Compuware is introducing zAdviser, a free product that leverages machine learning to help IT leaders make smarter data-driven decisions to drive continuous improvement of mainframe DevOps.
- zAdviser identifies patterns that impact quality, velocity and efficiency as they pertain to mainframe development by analyzing a customer's Compuware product usage data and DevOps key performance indicators (KPIs).
- zAdviser is fueled by the ongoing collaboration between customers and Compuware, where customers contribute their relevant DevOps data and Compuware contributes their mainframe expertise and machine learning insights.
DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. Based on key performance indicators (KPIs), zAdviser measures application quality, as well as development velocity and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts. zAdviser is free for Compuware customers on current maintenance.
The KPIs were developed based on extensive research with customers and align with those published in the 2018 Forrester report, "Use Four Key Categories To Measure What Matters In Continuous Deployment."
zAdviser leverages a set of analytic models that uncover correlations between mainframe developer behaviors and mainframe DevOps KPIs. These correlations represent the best available empirical evidence regarding the impact of process, training and tooling decisions on digital business outcomes. With this empirical evidence and associated recommendations, managers can make high-impact decisions about their mainframe DevOps methods with vastly improved speed and confidence.
Enterprises that outsource mainframe development can also reap significant value from zAdviser by using the analytical results to continuously achieve better business outcomes over time.
Improvements in mainframe DevOps is an imperative for large enterprises, which are becoming more dependent on mainframe applications-not less. According to a recent Forrester Consulting study commissioned by Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. That percentage is expected to increase to 64 percent by 2019, while at the same time enterprises are failing to replace the expert mainframe workforce they have lost by attrition.
According to the study, "As mainframe workload increases-driven by modern analytics, blockchain and more mobile activity hitting the platform-customer-obsessed companies should seek to modernize application delivery and remove roadblocks to innovation."
The Forrester Consulting study also highlights the importance of responding to these challenges with empirical insight: "KPIs like mean lead time, number of epics per deployment, and metrics that drive automation will harness velocity and efficiency, even as the skills gap of the workforce expands." The full study can be accessed here.
Compuware has been helping their customers qualify, quantify and increase the value derived from their Compuware products through its Value Improvement Program (VIP) for over 15 years. zAdviser is the next step in the evolution of the VIP and evidence-based mainframe process improvement, leveraging these years of experience helping enterprises modernize mainframe DevOps and improve mainframe staff performance.
zAdviser data inputs include both 1) metrics captured from Compuware tools, including behavioral data relating to feature utilization and 2) data captured from the customer's DevOps toolchain.
By aggregating input from customer sites across industries and around the world, Compuware is building the industry's richest repository of mainframe DevOps data-which combined with advanced machine learning methods generates unmatched insight for enterprise IT leaders.
"Our mainframe applications continue to play a critical role in delivering an excellent customer experience," said Steve Kalkowski, Assistant Vice President, The Hartford. "A product like Compuware zAdviser will give us the advanced analytics we need to drive our efforts towards improving developer speed and quality as we transition to an agile delivery model."
Compuware today also announced a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.
"Enterprises cannot afford to be even slightly complacent about the speed and excellence with which they update and evolve the core business logic of their mainframe applications," said Compuware CEO Chris O'Malley. "With zAdviser, Compuware is now offering a powerful, fact-based resource for IT leaders at the world's largest corporations to lead their critical mainframe modernization efforts-and to thereby sustainably derive maximum business value from their investments in mainframe hardware, applications and talent."
To learn more about zAdviser and get involved, visit us here.
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com .
Follow us on:
For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.
Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Inspiration in Receipt of Crypto Currency Proposal26.4.2018 16:54 | Pressemelding
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) is pleased to announce that it is contemplating upon the request of Compassion Cannabis that it is allowed to accept crypto currency for settlement for any transactions that occur. The logic is that it would make for easy settlement in any jurisdiction. The Company is not adverse to this proposal, but must perform its due diligence and will table the matter at the AGM. Compassion Cannabis is an Ontario Corp., which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. We believe this will be an extremely lucrative space with tremendous demand in the medical cannabis industry. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not revi
SNOMED International Announces Brazil as its 33rd Member26.4.2018 15:12 | Pressemelding
London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a foundational element of its ehealth Strategy, digiSUS. As outlined in this national strategy, the SUS Monitoring and Evaluation Department of Brazil's Ministry of Health is responsible overall for governance of the National Electronic Health Strategy and its related evaluation and development. Demonstrated through its membership in SNOMED International, Brazil has defined SNOMED CT as the chosen international reference terminology for use in its clinical systems supporting the national ehealth strategy. SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOME
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 201826.4.2018 14:30 | Pressemelding
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days. About Minerva Neurosciences Mine
Talend Data Fabric Now Certified on MapR Converged Data Platform Version 6.026.4.2018 14:11 | Pressemelding
Latest Release of Talend's Data Integration Platform Enables Powerful New Use Cases in Data Privacy, Compliance Monitoring, Claims Processing, Retail Optimization, and More REDWOOD CITY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, announced that the latest version of Talend Data Fabric is now certified for version 6.0 of the MapR Converged Data Platform, including MapR-DB and MapR-FS. The MapR Converged Data Platform is the industry's only enterprise-grade software solution that unifies big data and open source technologies with fast, native access to global event streaming, real-time database capabilities, and web-scale storage. Together, Talend and MapR provide a unified, open source-based data storage and management platform for an array of different applications, enabling organizations to harness big data in valuable ways to drive innovation and further their digital transformations. "Talend's powerf
CrownBio Launches New Humanized Target Model for Immunotherapy26.4.2018 14:00 | Pressemelding
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs. Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University. The CD3E model expresses the human form of CD3E and is phenotypically normal with levels
Jumio Achieves Record-Breaking Sales in Q1 2018, a 400% Increase Year-Over-Year26.4.2018 14:00 | Pressemelding
Spurred by growing traction in telecom, financial services and sharing economy, coupled with an increase in online fraud, Jumio announces best sales quarter to date PALO ALTO, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Jumio Corporation, the leading AI-powered trusted identity as a service, today announced the best sales quarter in company history. Led by strong sales in telecom, financial services and the sharing economy, Jumio grew Q1 2018 sales of its Netverify® solution by more than 400 percent compared to the same quarter last year. This represents the second quarter out of the last three where the company increased sales by more than 400 percent and the fifth consecutive quarter of increased sales. "The increasing reality of online fraud and well-publicized data breaches underscores the need to definitively establish someone's online identity, an issue which has never been more challenging or important," said Steve Stuut, CEO of Jumio. "Making matters worse, traditional methods o
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom